LON:SNG Synairgen (SNG) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Synairgen Stock (LON:SNG) Get Synairgen alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2.85 million shsAverage Volume1.63 million shsMarket Capitalization£9.04 millionP/E RatioN/ADividend Yield1.53%Price TargetN/AConsensus RatingN/A Company Overview Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016). The 220 patient trial comprises 100 patients to be initiated in hospital and 120 patients to be initiated in the home setting. A successful outcome will inform onwards progression of SNG001 in COVID-19 patients. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com Read More Receive SNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synairgen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNG Stock News HeadlinesFirst patient dosed in Synairgen’s global phase 2 INVENT studyDecember 8, 2025 | investing.comSynairgen Shares Plunge on AIM Delisting ProposalMarch 12, 2025 | marketwatch.comFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 14 at 1:00 AM | Porter & Company (Ad)Synairgen shares tumble over 23% after AIM delisting plansMarch 12, 2025 | finance.yahoo.comSynairgen Secures £18 Million Funding Amidst AIM Delisting PlansJanuary 16, 2025 | tipranks.comSynairgen Leads The Charge With 2 Other Promising Penny Stocks On UK ExchangeDecember 11, 2024 | uk.finance.yahoo.comBioventix PLC (BVXP.L) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comSynairgen Share Chat (SNG)September 17, 2024 | lse.co.ukSee More Headlines SNG Stock Analysis - Frequently Asked Questions How were Synairgen's earnings last quarter? Synairgen plc (LON:SNG) issued its quarterly earnings results on Tuesday, September, 29th. The company reported ($3.11) EPS for the quarter. How do I buy shares of Synairgen? Shares of SNG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Synairgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Synairgen investors own include Lloyds Banking Group (LLOY), AstraZeneca (AZN), Alibaba Group (BABA), boohoo group (BOO), Barclays (BARC), VanEck Gold Miners ETF (GDX) and Legal & General Group (LGEN). Company Calendar Last Earnings9/29/2020Today5/14/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:SNG CIKN/A Webwww.synairgen.com Phone+44-23-80512800FaxN/AEmployees34Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£15.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.06% Return on Assets-30.58% Debt Debt-to-Equity RatioN/A Current Ratio9.01 Quick Ratio6.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow1.90 Book ValueGBX 4.75 per share Price / BookN/AMiscellaneous Outstanding Shares977,714,692Free FloatN/AMarket Cap£9.04 million OptionableNot Optionable Beta-2.23 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:SNG) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersYou'll buy SpaceX at $1.75 trillion. Insiders bought at $20 billion.Insiders bought SpaceX at $20 billion. Banks got in at $100 billion. By the time it hits your brokerage accoun...Behind the Markets | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredNNVC FDA = New Momentum Wave!NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for its antiviral NV-387, targeting measl...Equiscreen | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMicroscopic Footage Shows Immune Cells Attacking CancerEarly human trial data from one NASDAQ-listed biotech showed up to a 63.7% reduction in cancer burden using it...Market Tactic | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synairgen plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Synairgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
